MedTrace Logo

Mesenchymal Stromal Cells for Acute Graft Versus Host Disease

NCT01589549 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 66

Last updated 2015-06-09

No results posted yet for this study

Summary

A randomised study of corticosteroid therapy with or without mesenchymal stromal cell therapy for newly diagnosed acute graft versus host disease after bone marrow transplantation or donor lymphocyte therapy.

It is hypothesised that mesenchymal stromal cell therapy will be superior

Conditions

  • Acute GVH Disease

Interventions

BIOLOGICAL

Mesenchymal stromal cell therapy

One arm will be randomised to receive mesenchymal stromal cell therapy in addition to corticosteroid therapy

Sponsors & Collaborators

  • Royal Perth Hospital

    collaborator OTHER

  • R.P.Herrmann

    lead OTHER

Principal Investigators

  • Duncan Purtill, MB, BS · Royal Perth Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-04-30
Primary Completion
2015-12-31
Completion
2016-12-31

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01589549 on ClinicalTrials.gov